Previous close | 75.27 |
Open | 74.76 |
Bid | 75.01 x 1400 |
Ask | 75.02 x 900 |
Day's range | 74.35 - 75.61 |
52-week range | 61.45 - 89.74 |
Volume | |
Avg. volume | 5,546,593 |
Market cap | 93.463B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 17.24 |
EPS (TTM) | 4.35 |
Earnings date | 25 Oct 2023 - 30 Oct 2023 |
Forward dividend & yield | 3.00 (3.99%) |
Ex-dividend date | 14 Sept 2023 |
1y target est | 85.46 |
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
FOSTER CITY, Calif., September 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can